Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
absence, add, agility, approach, Arginine, Asian, awarded, aware, Biomedical, biotech, borrowing, brentuximab, broad, burden, Chinese, cHL, choice, classical, concise, correct, countersued, declaratory, Deiminase, destructive, disciplined, Division, Dutch, duty, ehf, entrepreneurial, EPO, evident, examination, fiduciary, firm, force, Hodgkin, Honjo, immunoscience, inventorship, JCCP, Keytruda, Kingdom, Korman, leadership, lease, lesser, leverage, long, longest, lymphoma, maintain, maintained, MDL, monetary, monohydrate, Mylan, opposition, PAD, Padlock, par, permanently, petitioner, plateau, platinum, practicable, preemption, prepaid, presence, pretreated, prospective, PTC, pursue, reacquire, readily, reconsideration, Revlimid, revoked, rose, SCCHN, stem, stipulation, sued, Taiwan, top, treasury, unnamed, vedotin, ViiV, withheld
Removed:
abatacept, achievement, acquire, adequately, administered, advance, aggregate, aimed, amortized, approximate, assumed, ASV, asymptomatic, BCV, benchmark, beta, biopharma, Brazil, Bydureon, calcium, calculation, Calibr, Canada, carrying, CI, close, closing, collaborate, collect, combining, congestive, construct, continued, contract, create, daewoong, DCV, delivered, developing, discontinued, discount, discovering, disease, domestic, dual, earned, EGFR, ejection, eligible, entecavir, equal, equally, erosion, event, evolution, evolve, exercised, exit, exposure, factoring, FCPA, filling, floating, forecast, forecasted, formulation, fourth, fraction, gene, globally, Hanmi, hazard, heart, hedged, highly, imatinib, ImClone, immunology, immunotherapy, improve, inception, increasing, Indiana, ineffective, infected, infection, initiated, innate, inoperable, inquiry, instrument, invoiced, ipilimumab, Italy, IV, joint, key, KGaA, Korean, leading, located, manufacture, master, Mexico, minimally, modulating, molecule, monitored, Mount, Myalept, negative, nivolumab, objective, observed, occurring, offsetting, Ohio, Onglyza, open, originally, Otsuka, oversight, payable, peer, percentage, performed, personnel, platform, Portugal, privately, promotional, prostate, Prostvac, qualifying, RA, ratably, ratio, recorded, recourse, redemption, regulator, remeasured, remeasuring, reserve, responsibility, restore, restricted, restructuring, retain, retirement, returned, revised, ruled, satisfying, sensor, separately, shift, shown, simplified, small, sovereign, standalone, standpoint, substantially, sulfate, Symlin, symptomatic, synthesize, system, tablet, technology, temporarily, terminate, TGF, transformation, translation, Tribunal, ultimately, uncollectibility, underlying, uniQure, Valeant, variability, Vernon, vest, virology, weighted, workforce
Filing tables
Filing exhibits
Related press release
BMY similar filings
Filing view
External links
EXHIBIT 32b.
Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, Charles Bancroft, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (the Report), as filed with the Securities and Exchange Commission on April 28, 2016, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.
/s/ Charles Bancroft |
Charles Bancroft Chief Financial Officer |
April 28, 2016
E-32-2